Literature DB >> 24451000

Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction.

Petra Matoulková1, Petr Pávek, Josef Malý, Jiří Vlček.   

Abstract

INTRODUCTION: Due to their multiple effects, glucocorticoids (GCs) have versatile medical uses. They can regulate many xenobiotic-metabolizing enzymes of the cytochrome P450 (CYP) superfamily, and thus, influence pharmacotherapy. AREAS COVERED: The aim of this paper is to summarize the molecular effects of GCs on CYP as well as the available clinical evidence on drug-drug interactions (DDIs) between GCs and other drugs in which GCs influence the metabolism of other medicines through modifying CYP activity. We used the factographic database DRUGDEX® along with bibliographic searches. EXPERT OPINION: Most of the literature reported CYP3A4 induction by GCs, but this was not proved in all research. As the conclusions on these DDIs are conflicting, there are several issues to be considered like the dosage of GCs, the length of GCs treatment and concomitant therapy, all of which can have an additive inducing effect. Further, in designing a DDI study, crossover studies are preferred. A literature search of the abovementioned information resources provided dissimilar results.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24451000     DOI: 10.1517/17425255.2014.878703

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  13 in total

1.  Voriconazole hepatotoxicity as a result of steroid withdrawal in a patient with allergic bronchopulmonary aspergillosis.

Authors:  Sara Blanco-Dorado; Ana Teresa Marques Afonso; Enrique José Bandín-Vilar; Ignacio Novo-Veleiro; Fernando Ferrón Vidán; Ana Latorre-Pellicer; Olalla Maroñas Amigo; Anxo Fernández-Ferreiro; María Jesús Lamas
Journal:  Br J Clin Pharmacol       Date:  2018-12-09       Impact factor: 4.335

Review 2.  Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials.

Authors:  Charles Feldman; Ronald Anderson
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

Review 3.  Glucocorticoid treatment in juvenile idiopathic arthritis.

Authors:  Ezgi Deniz Batu
Journal:  Rheumatol Int       Date:  2018-10-01       Impact factor: 2.631

4.  Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report.

Authors:  Silvijus Abramavicius; Dzilda Velickiene; Edmundas Kadusevicius
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

Review 5.  p53: key conductor of all anti-acne therapies.

Authors:  Bodo C Melnik
Journal:  J Transl Med       Date:  2017-09-19       Impact factor: 5.531

Review 6.  Biologic Stress, Oxidative Stress, and Resistance to Drugs: What Is Hidden Behind.

Authors:  Maria Pantelidou; Karyofyllis Tsiakitzis; Eleni A Rekka; Panos N Kourounakis
Journal:  Molecules       Date:  2017-02-17       Impact factor: 4.411

Review 7.  [Pharmaceutical care for severe and critically ill patients with COVID-19].

Authors:  Saiping Jiang; Lu Li; Renping Ru; Chunhong Zhang; Yuefeng Rao; Bin Lin; Rongrong Wang; Na Chen; Xiaojuan Wang; Hongliu Cai; Jifang Sheng; Jianying Zhou; Xiaoyang Lu; Yunqing Qiu
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25

8.  Proteomic profiling of murine biliary-derived hepatic organoids and their capacity for drug disposition, bioactivation and detoxification.

Authors:  Lawrence Howell; Rosalind E Jenkins; Stephen Lynch; Carrie Duckworth; B Kevin Park; Christopher Goldring
Journal:  Arch Toxicol       Date:  2021-05-29       Impact factor: 5.153

Review 9.  Assessment of Vedolizumab Disease-Drug-Drug Interaction Potential in Patients With Inflammatory Bowel Diseases.

Authors:  Wan Sun; Richard A Lirio; Jennifer Schneider; Jiri Aubrecht; Harisha Kadali; Mike Baratta; Parul Gulati; Ajit Suri; Tiffany Lin; Raghavan Vasudevan; Maria Rosario
Journal:  Clin Pharmacol Drug Dev       Date:  2020-12-16

10.  Primary Human Hepatocytes, but Not HepG2 or Balb/c 3T3 Cells, Efficiently Metabolize Salinomycin and Are Resistant to Its Cytotoxicity.

Authors:  Lidia Radko; Małgorzata Olejnik; Andrzej Posyniak
Journal:  Molecules       Date:  2020-03-05       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.